BioSpace News Archive

Black Diamond Therapeutics, Inc. today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.

PhaseBio Pharmaceuticals, Inc. today provided an update on corporate activities and reported second-quarter 2021 financial results.

9 Meters Biopharma, Inc. today provided an overview of its recent achievements and reported financial results for the second quarter ended June 30, 2021.

atai Life Sciences, a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced the launch of Revixia Life Sciences, a wholly owned subsidiary developing Salvinorin A to treat a variety of mental health disorders.

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the appointment of Rosemary A. Crane to its Board of Directors.

Zealand Pharma Launches ZEGALOGUE® (dasiglucagon) Injection and Advances Pipeline Programs Across Multiple Therapeutic Areas

FEops, a leader in predictive planning for structural heart interventions, is proud to announce that its simulation technology supported TRiCares from initial design concept to a successful first-in-human of the Topaz Tricuspid Valve Replacement (TTVR) system, developed by TRiCares SAS.

Biomind Labs Inc. (“Biomind Labs” or the “Company”) (NEO: BMND), a leading biotech company in fast-acting psychedelics is pleased to announce that it has filed a patent application in the United States Patent and Trademark Office (USPTO), its 4th patent application.

Johnson & Johnson (NYSE: JNJ) will participate in the Morgan Stanley 19th Annual Global Healthcare Conference on Wednesday, September 15th.

Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions for which there are limited treatment options, reminds stockholders to vote on the proposals listed in the Company’s proxy statement in advance of its upcoming annual meeting.